West Pharmaceutical Services Inc (WST)
Health Care · Health Care Supplies · US stock · S&P 500 component
$384.02
▲ +1.00 (0.26%)
Fair valueOvervalued
$216 −43.8% to fair value
$108fair band $151–$281$324
Day's range
$380.28 – $386.26
52-week range
$223.52 – $386.26
About West Pharmaceutical Services Inc
West Pharmaceutical Services makes the packaging and delivery components that keep injectable medicines safe. Its rubber stoppers, seals and plungers are used in vials, syringes and cartridges, while its contract manufacturing business produces devices such as auto-injectors and other drug delivery products for drug makers. Customers are pharmaceutical, biotechnology and generic drug companies.
West earns revenue from the recurring supply of components used with each injection, and from contract manufacturing. Revenue for the last twelve months was $3.3 billion, growing at 2.1% a year across the last three years. The operating margin is 20.5%, and the business earns a profit of 19% on the capital invested in it. It has net debt of -0.1 times EBITDA, meaning slightly more cash than debt. A dividend is paid, with a yield of 0.2%. On the site's X-Ray Score it receives 44 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $223.52 – $386.26Volume 511,200Daily, split-adjusted
Vitals
Market cap$27.4B
52-week range$223.52 – $386.26
Volume (last day)511,200
P/E (TTM)49.1
EBIT / EV yield2.5%
Free-cash-flow yield1.6%
Dividend yield0.2%
Revenue (TTM)$3.3B
Net income (TTM)$565M
Operating margin20.5%
Return on capital18.8%
Debt incl. leases$312M
Cash & securities$436M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$216model spread $205 – $228
Overvalued
−43.8% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $384
Undervalued < $151Fair $151 – $281Overvalued > $281
10-year DCF (market-scaled)
$223
Peer multiples
$215
Earnings power floor (not blended)
$98
Fundamentals-adjusted multiple
$211
Growth the price implies
27.9%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
17/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield2.5%
Free-cash-flow yield1.6%
Fair value vs price0.6×
Growth
Weak
30/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)2.1%
EPS growth (3y)-4.2%
Growth consistency70%
Profitability
Fair
52/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital18.8%
Operating margin20.5%
Gross profitability30.0%
Financial health
Strong
82/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score7 / 9
Net debt / EBITDA-0.1×
Interest coverNo interest cost
Dividends
Weak
49/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.2%
Dividends vs free cash flow14%
Dividend growth4.2%
Quarterly results: last 6 quarters
+0.4%
Mar '25
+9.2%
Jun '25
+7.7%
Sep '25
+7.5%
Dec '25
+21.0%
Mar '26
+13.8%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $872M, diluted EPS $2.15.
Compare with peers
ALGN Align Technology Inc61 COO Cooper Companies, Inc.46Other Health Care Supplies companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 4 Average · ● 7 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldBad
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverGood
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalGood
Operating marginAverage
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 44/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Operating income | $752M | $734M | $676M | $570M | $585M |
| Net income | $662M | $586M | $593M | $493M | $494M |
| Operating cash flow | $584M | $724M | $777M | $653M | $755M |
| Operating margin | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Free cash flow | $331M | $439M | $415M | $276M | $469M |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 372.6 | Bullish |
| EMA 10 | 374.3 | Bullish |
| SMA 20 | 371.6 | Bullish |
| EMA 20 | 370.0 | Bullish |
| SMA 50 | 358.1 | Bullish |
| EMA 50 | 360.4 | Bullish |
| SMA 100 | 349.5 | Bullish |
| EMA 100 | 345.3 | Bullish |
| SMA 200 | 307.1 | Bullish |
| EMA 200 | 321.4 | Bullish |
Oscillators (daily)
| RSI (14) | 65.57 | Neutral |
| MACD (12, 26) | 5.53 | Bullish |
| Momentum (12) | 3.58 | Bullish |
| Stochastic %K (14) | 91.63 | Bearish |
| Williams %R (14) | -8.37 | Bearish |
| CCI (20) | 189.6 | Bearish |
Pivot points (classic, last session)
S3 374.8 | S2 377.5 | S1 380.8 | Pivot 383.5 | R1 386.8 | R2 389.5 | R3 392.7 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.88 USD
Yield on today's price
0.23%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 29 Jul 2026 | 0.2200 |
| 29 Apr 2026 | 0.2200 |
| 28 Jan 2026 | 0.2200 |
| 12 Nov 2025 | 0.2200 |
| 30 Jul 2025 | 0.2100 |
| 30 Apr 2025 | 0.2100 |
| 7 Feb 2025 | 0.2100 |
| 13 Nov 2024 | 0.2100 |
| 31 Jul 2024 | 0.2000 |
| 23 Apr 2024 | 0.2000 |
| 30 Jan 2024 | 0.2000 |
| 7 Nov 2023 | 0.2000 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
WST SEC filings
23 Jul 2026
10-QSEC EDGAR
Quarterly report
23 Jul 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
14 Jul 2026
8-KSEC EDGAR
Entered a material agreement
1 Jun 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
11 May 2026
8-KSEC EDGAR
Regulation FD disclosure
5 May 2026
8-KSEC EDGAR
Shareholder vote results
23 Apr 2026
10-QSEC EDGAR
Quarterly report
23 Apr 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.